Saving PRMT5 Drug Development with Metabolomics
How Metabolomic Biomarkers Could Save PRMT5 Drug Development The PRMT5 inhibitor field represents one of the most expensive lessons in modern oncology drug development. Despite massive investments – including Bristol Myers Squibb’s $4.8 billion acquisition...
Metabolic Signatures Reveal Molecular Glue Activity
Linking Protein Degradation to Functional Metabolic Consequences Molecular glue degraders induce targeted protein degradation through E3 ligase modulation, but measuring protein loss alone provides an incomplete picture of therapeutic activity. The functional...
Predict Responders in mRNA Trials via Metabolomics
Biomarker-Driven mRNA Trials: How Discovery Metabolomics Finds the Responders Before Treatment Your Phase 2 mRNA therapeutic trial enrolled sixty patients. Twenty showed remarkable responses. Thirty had modest benefits. Ten showed no response at all. Now you’re...
Metabolomic Logic Behind MAT2A/PRMT5 Combinations
Two Targets, One Pathway: The Metabolomic Logic Behind MAT2A/PRMT5 Combination Therapies The next breakthrough in cancer treatment may come from attacking two targets within the same metabolic pathway. MAT2A and PRMT5 inhibitor combinations represent a new paradigm in...